Please enter the information you want to find
Hot key words：
The core business of Shanghai Bao Pharmaceuticals Co. Ltd. (Bao Pharma) focuses on the industrialization and commercialization of recombinant protein drugs and antibody drugs. The company is currently constructing a modern biopharmaceutical industrial base that complies with GMP standards in the Luodian Industrial Park in Baoshan District, Shanghai, with a total investment exceeding 900 million RMB. The facility is planned to include multiple bulk production lines utilizing both mammalian cell expression systems and bacterial/yeast expression systems. It will also feature finished dosage production lines for injectable solutions, lyophilized powder injections, and single-use prefilled syringes.
Since
2011
Clinical trial success rate
66.6
%
R&D investment
33.3
%
In August 2011, Suzhou Kangju Biotechnology Co., Ltd. (“Kangju”) was established in Suzhou Industrial Park, focusing on the development of recombinant enzyme drugs and monoclonal antibodies.
In July 2014, Suzhou Centergene Pharmaceuticals Co., Ltd. (“Shengji”) was established in Suzhou Industrial Park, focusing on the development of glycoprotein drugs (assisted reproductive product line).
In December 2019, Shanghai Bao Pharmaceuticals Co., Ltd. was established in Luodian Industrial Park, Baoshan District, Shanghai. Bao Pharma integrated Kangju and Centergene to take over existing projects and accelerate their industrialization process.
Completed RMB 474 million Series A financing in March 2021.
Acquired 94 mu (approx. 15.5 acres) of land and a 25,000-square-meter facility at 50 Luoxin Road from Shanghai Jingfeng Pharmaceutical Co., Ltd. in October 2021, enabling Bao Pharma to achieve industrial-scale biopharmaceutical production.
Completed RMB 585 million Series B financing in August 2022.
Obtained the “Drug Manufacturing License” issued by the Shanghai Administration of Pharmaceuticals and Medical Devices in December 2022 for the production of therapeutic biological products (recombinant human hyaluronidase for injection).
Obtained the “Drug Manufacturing License” from the Shanghai Administration of Pharmaceuticals and Medical Devices in May 2023 to manufacture recombinant human follicle-stimulating hormone-CTP fusion protein injection developed by its subsidiary, Centergene.
In December 2023, Suzhou Centergene Pharmaceutical Co., Ltd. submitted a marketing application for recombinant human follicle-stimulating hormone-CTP fusion protein injection to the National Medical Products Administration
Bao Pharma submitted an application to the National Medical Products Administration for the market launch of its recombinant human hyaluronidase for injection.
